If you are still deciding whether prescription support is right for you, complete the free assessment quiz to see whether a personalized program may be a fit for your goals
1 The FLOW trial achieved its primary endpoint with Ozempic 1 mg, demonstrating a statistically significant and superior 24% relative risk reduction of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease (4.9% absolute risk reduction at 3 years) compared to placebo, when added to standard of care
Irregular use can reduce the medication's effectiveness and make it harder to maintain appetite control
New England Journal of Medicine, 392(7), 612615
What affects KLOW results
The risk of clinically significant insomnia outweighs the benefit of partial afternoon coverage